by admin | Mar 26, 2013 | Uncategorized
Eritoran, a promising first-in-class agent for combating Gram-negative sepsis, failed its Phase 3 clinical trial, according to the results of the ACCESS trial published in the March 20th issue of JAMA. Eritoran is synthetic lipid A antagonist that blocks...
by admin | Mar 20, 2013 | Uncategorized
Early antibiotic administration is a critical step in appropriate sepsis care. However, overuse and misuse of antibiotics, including the unnecessarily prolonged use of antibiotics, can have adverse effects and lead to increased microbial resistance. A Comparative...
